

Document downloaded from:

<http://hdl.handle.net/10251/183953>

This paper must be cited as:

Molero-Alabau, R.; Soler Torro, JM.; Martínez Alzamora, MN.; Climent, AM.; Guillem Sánchez, MS. (2021). Higher reproducibility of phase derived metrics from electrocardiographic imaging during atrial fibrillation in patients remaining in sinus rhythm after pulmonary vein isolation. *Computers in Biology and Medicine*. 139:1-7.  
<https://doi.org/10.1016/j.combiomed.2021.104934>



The final publication is available at

<https://doi.org/10.1016/j.combiomed.2021.104934>

Copyright Elsevier

Additional Information



23 **Abstract**

24 **Background:** Electrocardiographic imaging (ECGI) allows evaluating the complexity of the  
25 reentrant activity of atrial fibrillation (AF) patients. In this study, we evaluated the ability of ECGI  
26 metrics to predict the success of pulmonary vein isolation (PVI) to treat AF.

27 **Methods:** ECGI of 24 AF patients (6 males, 13 paroxysmal,  $61.8 \pm 14$  years) was recorded prior  
28 to PVI. Patients were distributed into two groups based on their PVI outcome 6 months after  
29 ablation (sinus vs. arrhythmia recurrence). Metrics derived from phase analysis of ECGI signals  
30 were computed for two different temporal segments before ablation. Correlation analysis and  
31 variability over time were studied between the two recorded segments and were compared  
32 between patient groups.

33 **Results:** Temporal variability of both rotor duration and spatial entropy of the rotor histogram  
34 presented statistical differences between groups with different PVI outcome ( $p < 0.05$ ). The  
35 reproducibility of reentrant metrics was higher ( $R^2 > 0.8$ ) in patients with good outcome rather than  
36 arrhythmia recurrence patients ( $R^2 < 0.62$ ). Prediction of PVI success based on ECGI temporal  
37 variability metrics allows for an increased specificity over the classification into paroxysmal or  
38 persistent (0.85 vs. 0.64).

39 **Conclusions:** Patients with favorable PVI outcome present ECGI metrics more reproducible over  
40 time than patients with AF recurrence. These results suggest that ECGI derived metrics may allow  
41 selecting which patients would benefit from ablation therapies.

42

43

44 **Keywords:** Atrial Fibrillation; Electrocardiographic Imaging; Reproducibility; Reentrant  
45 Activity; Pulmonary Vein Isolation

46

47 **Abbreviations**

48 AF Atrial Fibrillation

49 AUC Area Under the Curve

50 ECGI Electrocardiographic Imaging

51 IVC Inferior Vena Cava

52 LIPV Left Inferior Pulmonary Vein

53 LSPV Left Superior Pulmonary Vein

54 PVI Pulmonary Vein Isolation

55 RIPV Right Inferior Pulmonary Vein

56 ROC Receiver Operating Characteristic Curve

57 RS Reproducibility Score

58 RSPV Right Superior Pulmonary Vein

59 SP Singularity Point

60 SVC Superior Vena Cava

61 VS Variability Score

62 **1. Introduction**

63 Atrial fibrillation (AF) is the most prevalent arrhythmia in the adult population [1], and it causes  
64 a major burden both in the patients and in health systems [2]. Although restoration of sinus rhythm  
65 would be desirable in the entire AF population of patients this is not always feasible. When drug  
66 therapies fail in restoring sinus rhythm or in minimizing AF-related symptoms, patients can be  
67 referred for catheter ablation [2]. Pulmonary vein isolation (PVI) is recommended for patients  
68 with paroxysmal AF and persistent AF with low risks of AF recurrence, but despite these  
69 recommendations, the percentage of AF recurrence in ablated patients is still high and around  
70 40% [3]. It has been reported that driver-guided catheter ablation of atrial areas with other lesions  
71 can reduce AF recurrence after the ablation [4,5] but the most recent guidelines for AF  
72 management still recommend further evidence before changing the current recommendations [2].

73 Electrocardiographic imaging (ECGI) is a non-invasive technique that has shown its ability to  
74 estimate the electrical activity of AF patients. ECGI has been used with success to guide ablations  
75 based on driver identification [5,6,7] and more recent studies have reported a good correlation  
76 between invasively and ECGI-derived estimation of the complexity of the electrical patterns  
77 during AF [8]. ECGI derived metrics of complexity have been shown to be related to the disease  
78 progression, and more complex patterns are typically present in persistent AF patients as  
79 compared to paroxysmal AF patients [9]. However, these complexity metrics have not been  
80 related to a differential outcome prediction.

81 The objective of this study is to evaluate the potential of ECGI derived complexity metrics as an  
82 indicator of PVI success. We hypothesized that the reproducibility of ECGI complexity metrics  
83 can be related to the complexity of the arrhythmia and the outcome of PVI to a larger extent than  
84 the complexity estimated at a single temporal interval. We compared ECGI derived metrics of AF  
85 patients prior to PVI obtained at different time segments and evaluated its variability in time in  
86 patients with and without arrhythmia recurrence 6 months after PVI.

87 **2. Methods**

88 2.1. Study Population

89 A population of 24 atrial fibrillation patients (18 females and 6 males;  $61.8 \pm 14.3$  years old) was  
90 studied prior to a wide antral circumferential pulmonary vein isolation procedure. Patients gave  
91 informed consent, and the protocol was approved by the ethics committee of Hospital Gregorio  
92 Marañón, Madrid, Spain (reference 475/14). Consecutive patients from this Clinical Trial that had  
93 two or more signal segments with AF recorded prior valvuloplasty and PVI were selected for  
94 being able to study the reproducibility of the metrics. Five patients of a totality of 29 did not  
95 present two AF signals prior the procedure with enough quality to be analyzed and were removed  
96 from the present study. Out of the 24 patients, 13 were classified as paroxysmal AF and 11 as  
97 persistent AF and 10 patients had valvular insufficiency. A percutaneous balloon mitral  
98 valvuloplasty was performed on patients with valvular diseases prior PVI. In procedure, patients  
99 in sinus rhythm, AF, it was induced by decremental pacing at the pulmonary veins. A total of 6  
100 patients were under antiarrhythmic drugs (flecainide  $n=1$ , amiodarone  $n=5$ ). Patients were  
101 followed 6 months after the ablation and then grouped into either sinus rhythm ( $N=13$ ) or  
102 arrhythmia recurrence (atrial fibrillation, atrial tachycardia or atrial flutter,  $N=11$ , see Table 1). A  
103 12 lead ECG and quality-of-life questionnaires were used for detecting arrhythmia recurrences 6  
104 months after the PVI.

105

	<b>All Patients (n = 24)</b>	<b>Sinus (n=13)</b>	<b>Arrhythmia Recurrence (n=11)</b>
<b>Male (%)</b>	6 (25 %)	5 (38.46 %)	1 (9.1 %)
<b>Age (Years)</b>	$61.83 \pm 14.03$	$59.23 \pm 14.01$	$64.91 \pm 13.43$

<b>Paroxysmal AF (%)</b>	13 (54.17 %)	9 (69.23 %)	4 (36.36 %)
<b>Valvuloplasty (%)</b>	10 (41.67 %)	7 (53.85 %)	3 (27.27 %)
<b>Medical Therapy</b>	Flecainide – 1 Amiodarone – 5	Flecainide – 1 Amiodarone – 2	Amiodarone – 3
<b>Medical Therapy after Ablation</b>	Amiodarone – 6 Flecainide -2 Beta-Blockers - 8	Amiodarone – 4 Flecainide -2 Beta-Blockers - 4	Amiodarone – 2 Beta-Blockers - 4
<b>Patients with Previous Ablations</b>	23 (95.8%)	12 (92.3%)	11 (100%)
<b>Previous Ablations per Patient</b>	1.21 ± 0.5	1.15 ± 0.55	1.27 ± 0.44
<b>Left Ventricular Ejection Fraction (%)</b>	56.48 ± 6.92	59 ± 6.14	53.73 ± 6.91
<b>Left Atrium Size (cm<sup>2</sup>)</b>	32.7 ± 7.41	33.35 ± 8.27	31.94 ± 6.54

106 **Table 1.** Clinical description of the study population

107 2.2. Data Acquisition

108 We recorded surface ECG signals from the patients at 57 locations on the torso surface before  
109 pulmonary vein isolation and valvuloplasty. Signals were recorded with 0.05 to 500 Hz filtering

110 and a sampling frequency of 1 kHz [8]. The geometry of the torso of the patients and the electrode  
111 location were obtained using video recording and reconstructed by photogrammetry [10]. Images  
112 from the video were exported and common image pixels were used for 3D-torso reconstruction.  
113 A 3D-torso mesh and the corresponding texture was used for electrode location identification.  
114 MRI/CT scan images were also obtained before the intervention and both the atria and the torso  
115 were segmented semi-automatically when geometries were well defined or manually layer by  
116 layer using ITK-SNAP when necessary [8] [11]. Torso and atrial geometries were co-registered  
117 using the torso reference from MRI/CT images.

### 118 2.3. Data processing

119 To study the reproducibility among time of ECGI-extracted metrics, raw signals of two segments  
120 of each patient ( $4 \pm 0.31$ s) were selected prior to PVI. The signals were preprocessed removing  
121 the baseline and were band-pass filtered between 2 and 45 Hz to eliminate noise using a 10<sup>th</sup> order  
122 Butterworth filter, and ventricular activity (QRST segment) was canceled lead by lead by using  
123 the Principal Component Analysis approach [12]. Inverse computed electrograms were calculated  
124 by using zero-order Tikhonov regularization and L-curve optimization [13] for each segment. We  
125 applied Hilbert's transform to the ECGI signals to compute the instantaneous phase of each signal.  
126 Reentrant activity was defined as a phase progression from  $-\pi$  to  $+\pi$  around a single point in the  
127 epicardium. Singularity points (SP) were then defined as stable rotations around an atrial point  
128 for at least 1 turn in at least two out of three concentric rings of increasing radii as described  
129 elsewhere [14]. The distance threshold between SP at consecutive time instants to considered SP  
130 related to form a rotor was 1 cm [14]. SP histograms were constructed to represent the cumulative  
131 SPs in each node of the epicardium, where a higher accumulation of SP detected represent areas  
132 with more frequent pivoting electrical activity [8].

### 133 2.4. Atrial fibrillation complexity quantification

134 To evaluate the reentrant activity and the complexity of the arrhythmia in each patient, different  
 135 metrics of the signals were computed in the two segments recorded of each patient. Total  
 136 singularity points were computed as the number of phase singularities detected scaled by time  
 137 (SP/ms). Mean rotor duration (Rduration) was computed as the mean duration in seconds of the  
 138 detected rotors in the signal. Finally, the Shannon spatial entropy of the SP histogram was  
 139 computed.

#### 140 2.5. Reproducibility measurements

141 To study the reproducibility of each metric, the variability of AF complexity metrics in time was  
 142 computed as the absolute difference between the metrics extracted from the two different temporal  
 143 segments:  $\Delta SP/ms$ ,  $\Delta Rduration$  and  $\Delta Entropy$  were computed as the absolute differences between  
 144 SP/ms, Rduration and Entropy measured in interval 1 and 2, respectively. In addition, the  
 145 Coefficient of determination ( $R^2$ ) between the first and second metrics was computed.

146 An additional quantification of the reproducibility of the different metrics was computed as the  
 147 ratio between the intra-patient variability and the variability between subjects: the variability  
 148 score (VS), see Equation 1[15].

$$VS = \frac{\text{Intrasubject Variability}}{\text{Intersubject Variability}} = \frac{|(X1 - X2)|}{\frac{|(X1 + X2)|/2}{\frac{\sigma_{X1}}{\mu_{X1}}}} \quad (1)$$

149 Where X1 is any metric at time interval 1 (namely SP/ms, mean rotor duration, or spatial  
 150 Shannon's entropy), X2 is the same metric computed for interval 2,  $\sigma_{X1}$  is the standard deviation  
 151 of X1 and  $\mu_{X1}$  is the mean value of X1. The lower the VS values, the higher the reproducibility  
 152 of the metric. Overall, a VS value lower than 1 is assumed to represent a reproducible metric.

#### 153 2.6. Statistical analysis

154 In order to compare complexity metrics between groups (restoration of sinus rhythm vs.  
 155 arrhythmia recurrence or paroxysmal vs. persistent), mean values of the metrics of the first and

156 second interval were computed. Normality of the values of each patient's group was computed  
157 using the Kolmogorov-Smirnov test. To study differences between groups, student's t-test was  
158 computed to compare normal samples and Wilcoxon rank-sum test was computed to compare  
159 non-normal samples. A  $p$ -value $<0.05$  was considered statistically significant. Statistical  
160 differences in the  $R^2$  between groups were computed using a tail t-test after Fisher r-to-z  
161 transform.

## 162 2.7. Outcome prediction based on ECGI reproducibility


163 A reproducibility score (RS) was computed as the average between  $\Delta R_{duration}$  and  $\Delta Entropy$  in  
164 order to predict 6-months outcome of PVI. Univariate logistic regression of RS was performed to  
165 predict the PVI outcome. Sensitivity and specificity were also computed based on the threshold  
166 determined from the regression analysis and subsequent receiver operating characteristic curves  
167 (ROC) and area under the curve (AUC) were computed. Furthermore, univariate logistic  
168 regression was computed using AF type as a predictor of PVI outcome, to compare the proposed  
169 method with the current standards for selecting PVI candidates. Finally, univariate logistic  
170 regression was also computed for the determination of the AF type (paroxysmal vs. persistent)  
171 based on the reproducibility score to see if RS is related to AF type.

172

## 173 **3. Results**

174 Two sample cases and their phase maps and SP histograms are represented in Fig. 1, including  
175 one patient that maintained sinus rhythm 6 months after PVI (Fig 1A) and one patient in which  
176 AF recurred (Fig. 1B). Phase maps from the first and second time interval in a patient with an  
177 effective PVI do show reentries, mainly around the Right Inferior Pulmonary Vein (RIPV) and  
178 therefore rotor histogram maps show a larger incidence at the RIPV, together with some  
179 occurrences at other pulmonary veins. Phase maps of the patient with an ineffective PVI show a  
180 more complex pattern, with a more inhomogeneous propagation. Rotor histogram in this patient,

181 therefore, showed more reentries in both atria, including the pulmonary veins but also the inferior  
 182 vena cava (IVC) and other sites in the right atrium. Although rotor maps obtained from the same  
 183 patient at different time instants do show large incidence areas at similar locations, the  
 184 reproducibility is larger in the patient in which PVI was effective.




185

186 **Fig. 1.** Phase map and singularity points histogram of the first and second segment of the signal  
 187 of a patient that had sinus rhythm 6 months after PVI (A) and a patient with arrhythmia recurrence  
 188 after ablation (B).

### 189 3.1. Reproducibility of ECGI metrics vs. patient outcome

190 Values for all the complexity metrics for patients with an effective and an ineffective PVI are  
 191 presented in Figure 2. As it can be observed no statistical differences between the two groups  
 192 were found in any of the parameters and, therefore, neither the amount of SP/ms found nor their  
 193 duration or the entropy of the rotor histogram maps may allow anticipating in which patients PVI  
 194 might be effective.




195

196 **Fig. 2.** Mean values between first and second measurements for each metric for each patient group  
 197 (white: good PVI outcome, black: bad PVI outcome) and p-value from the Wilcoxon rank-sum  
 198 test between groups of singularity points per millisecond (A), mean rotor duration (B) and spatial  
 199 entropy (C).

200

201 Scatter plots of the metrics in the first segment versus the second temporal segment for both  
 202 groups of patients and each metric are presented in Fig. 3. As it can be observed, there is some  
 203 reproducibility in the measurements since metrics from the first temporal segment are closely  
 204 related to those in the second temporal segment and this correlation is higher for patients with a  
 205 successful PVI than for patients with an unsuccessful PVI. In fact, the  $R^2$  values are higher for  
 206 patients with favorable outcome and all measurements: SP/ms ( $R^2=0.87$  vs.  $0.36$ ,  $p=0.04$ ), spatial  
 207 entropy ( $R^2=0.87$  vs.  $0.39$ ,  $p=0.05$ ) or mean rotor duration ( $0.82$  vs.  $0.62$ ,  $p=n.s.$ ).




208

209 **Fig. 3.** Scatter plots of the first and second measurements for each metric classified by PVI  
 210 outcome (gray: good outcome), black (bad outcome): singularity points per millisecond (A), mean  
 211 rotor duration (B) and spatial entropy (C).

212

213 Differences in the metrics between the first and second segment showed a similar trend than the  
 214  $R^2$  values: differences were significant both of the mean rotor duration and spatial entropy (Fig.  
 215 4), ( $p=0.03$  and  $p=0.04$ , respectively).



216


217 **Fig. 4.** The absolute difference between the two measurements for each metric and group of  
 218 patients (white: good PVI outcome, black: bad PVI outcome) is presented with the p-value from

219 the Wilcoxon rank-sum test of singularity points per millisecond (A), mean rotor duration (B) and  
220 spatial entropy (C).

221

222 Intersubject variability against the intrasubject variability of each metric is shown in Fig. 5A. All  
223 the metrics presented a good reproducibility based on this criterium: variability among patients  
224 was higher than for the same patient and therefore, all pairs of values are below the identity line.

225 Patients with a successful PVI presented both a lower intrasubject variability and intersubject  
226 variability for all metrics (white colored in Fig. 5A and B), showing a better reproducibility in  
227 comparison with the unsuccessful PVI. The number of SP/ms and spatial entropy presented higher  
228 differences between groups of the patients regarding intersubject variability. Mean rotor duration  
229 presented the lowest differences between groups. Variability scores, shown in Fig.5.B show the  
230 same tendency of the  $R^2$  values: patients with good PVI outcome showed lower variability scores  
231 than patients with arrhythmia recurrence. Furthermore, differences in the value of  $R^2$  and  
232 variability score between these two groups of patients are consistent, observing the highest  
233 differences in SP/ms and spatial entropy.




234  
235 **Fig. 5.** A. Intersubject variability vs intrasubject variability of the metrics calculated. Color  
236 indicates the classification of the patients and shape the metric. The area under the line shows the  
237 metrics that are in the optimal area where intersubject variability is lower than the variability

238 between patients. B. Results for the variability score between the studied metrics and patients  
239 classified by PVI outcome.

240

### 241 3.2. ECGI Reproducibility vs. AF type

242 A comparison between metrics and their variability between groups of patients based in AF type  
243 (paroxysmal/persistent) is presented in Fig. 6. When patients are classified by AF type, there are  
244 no major differences in the mean value of metrics, as it happens when grouping the patients  
245 according to the PVI outcome. Differences between first and second measurements, however,  
246 were significant for the number of singularities detected, but not on the rotor duration or spatial  
247 entropy.



248

249 **Fig. 6.** Mean values between first and second measurements for each metric are presented in A  
250 for each patient group based on AF diagnosis (white: paroxysmal AF, black: persistent AF) and

251 p-value from the Wilcoxon rank-sum test between groups. The absolute difference between the  
252 two measurements for each metric and group of patients is presented with the p-value from the  
253 Wilcoxon rank-sum test in B.

254

255 3.3. Association of PVI success based on ECGI variability metrics

256 Univariate logistic regression of the proposed reproducibility score was computed with the two  
257 metrics that showed lower p-values when compared groups based on PVI outcome ( $\Delta R_{duration}$   
258 and  $\Delta Entropy$ ). Results showed an area under the curve of 0.77. Area under the curve of RS for  
259 classification into paroxysmal or persistent AF was lower: 0.59, which highlights that the  
260 proposed reproducibility score based on ECGI metrics is more closely related to the PVI outcome  
261 than the AF classification.

262 Prediction of PVI success according to their diagnosis into paroxysmal or persistent AF, assuming  
263 that patients with paroxysmal AF will have a favorable outcome of PVI whereas patients with  
264 persistent AF will have a poor PVI outcome offered a sensitivity of 0.63 and a specificity of 0.69.  
265 Prediction based on our reproducibility score, in contrast, resulted in a sensitivity of 0.64 and a  
266 specificity of 0.85, and therefore, the use of ECGI reproducibility measurements may allow in  
267 better selecting patients that will not benefit from PVI.

268

#### 269 **4. Discussion**

270 In this work, we have evaluated the variability of reentrant activity metrics extracted before PVI  
271 in AF patients and found a relation between this variability and PVI outcome six months after the  
272 procedure. We have found that the electrical patterns of patients with a successful PVI are more  
273 stable in time than those of patients with an unsuccessful PVI. Temporal variability of ECGI

274 metrics during AF may allow for a better prediction of PVI outcome than the classification into  
275 paroxysmal or persistent AF.

#### 276 4.1. Mechanism of AF and PVI outcome

277 Prior studies by Haissaguerre *et al.* [5], Narayan *et al.* [6], and others [4, 16] have demonstrated  
278 that ablation of rotors and focal sites does result in a better prognosis than PVI only. In this same  
279 direction, Gao *et al.* reported higher reentrant activity in ECGI maps for patients with acute  
280 termination of PVI [9]. These previous studies used a vest of 252 electrodes for ECGI calculation,  
281 and in the present study, 57 individual electrodes were used. Despite that a lower number of  
282 electrodes used, it was demonstrated in previous studies [17][18] that 32 electrodes are enough  
283 for a proper ECGI reconstruction. Furthermore, a good correlation of ECGI and intracardiac AF  
284 complexity evaluation with this electrode configuration has been previously shown [8]. Although  
285 we were anticipating that patients with successful PVI ablations would present differences in  
286 either the number of rotors or their duration as compared with patients with unsuccessful ablations  
287 we have not found significant differences in rotor metrics. Zaman *et al.* [19], found that patients  
288 with paroxysmal AF recurrence after PVI had extra-PV sources, matching with our observations  
289 with more unstable reentrant activity in arrhythmia recurrence patients independently of the  
290 diagnosis. Therefore, the presence of rotors outside the pulmonary vein area in some patients may  
291 be one of the reasons behind our unobserved differences in primary rotor metrics in our patients  
292 with successful versus unsuccessful ablations. However, we believe that this observation can also  
293 be attributed to the characteristics of our cohort of patients since most of them presented a very  
294 damaged atrial substrate as a consequence of an increased atrial pressure due to the valvular  
295 impairment that may result in a low incidence of driving rotors.

#### 296 4.2. Temporal reproducibility of ECGI derived metrics

297 We have found that patients with a good prognosis after PVI showed a more stable electrical  
298 activity in terms of the variability in time of rotational quantification metrics. This is consistent

299 with many reports in the literature that have demonstrated a lower temporal recurrence on  
300 electrophysiological metrics in patients with persistent AF versus patients with paroxysmal AF  
301 [20]. Lim et al [21] and others [20, 21] found that the complexity of persistent AF drivers is higher  
302 when AF duration increases.

303 Our observation would also be consistent with other studies that have related an electrical  
304 temporal instability with lower rates of maintenance of sinus rhythm either after PVI [24] or  
305 electrical cardioversion [25].

#### 306 4.3. Clinical implications

307 Catheter ablation is mainly recommended for paroxysmal AF patients based on overall lower AF  
308 recurrence after ablation in this group of patients [2]. However, there are both paroxysmal AF  
309 patients that do not benefit from PV ablation and persistent AF patients that do benefit from PVI.  
310 In our study, we have observed that temporal stability of ECGI derived rotor metrics may help to  
311 predict the success of PVI and, therefore, better select patients likely to benefit from PVI and  
312 discard the ones that will not, to tailor the treatment to AF in an individual basis with  
313 electrophysiological measurements from individual patients instead of the “one approach fits all”  
314 approach currently used today.

315

#### 316 **5. Limitations**

317 The results of this study should be confirmed in larger datasets and compared to endocardial data.  
318 Our results may also be influenced by our study population, with a large proportion of patients  
319 with valvular disease. Although we did not find statistical differences in any of the variability of  
320 metrics when comparing valvular impaired patients with non-valvular impaired AF patients, we  
321 cannot rule out the possible effect of a substantially damaged atrial substrate that may not be  
322 representative of a more general AF population. Time separation between signals was established  
323 between 15s to 10 minutes due to the difficulties of some patients of maintaining AF during the

324 procedure and reproducibility in time was not considered during the PVI protocol. Furthermore,  
325 it should be noted that the outcome of the studied patients could be influenced by changes in the  
326 medication, the extent and durability of transmural ablation lesions and that this could influence  
327 the results. Follow up of the patients was done 6 months after PVI and could not determine if the  
328 recurrence of the arrhythmia would be caused by PVI reconnection and not because of the atrial  
329 substrate. The fact that durable PVI can occur although the substrate of the atria may remain  
330 abnormal should be considered together with the possibility of arrhythmia recurrence after the 6  
331 months follow up.

332

## 333 **6. Conclusions**

334 This study shows that ECGI derived metrics of reentrant activity in atrial fibrillation patients are  
335 reproducible over time and the degree of this reproducibility may be indicative of their electrical  
336 substrate since patients with more reproducible metrics are associated with a more favorable  
337 outcome. Therefore, variability of rotor metrics derived from ECGI may be suggestive of the  
338 ability of PVI to terminate the arrhythmia and may serve for selecting the best treatment option  
339 in AF patients.

340

## 341 **Acknowledgments**

342 The authors wish to thank Dr. Felipe Atienza for his support of the project and clinical advice.

343

## 344 **Funding Sources**

345 This work was supported by: Instituto de Salud Carlos III, and Ministerio de Ciencia, Innovación  
346 y Universidades (supported by FEDER Fondo Europeo de Desarrollo Regional PI17/01106 and

347 RYC2018-024346B-750), EIT Health (Activity code 19600, EIT Health is supported by EIT, a  
348 body of the European Union) and Generalitat Valenciana Grants (ACIF/2020/265).

349

### 350 **Disclosures**

351 MS Guillem and A Climent are co-founders and shareholders of CORIFY Inc.

352

### 353 **References**

354 [1]E.J. Benjamin, P. Muntner, A. Alonso, M.S. Bittencourt, C.W. Callaway, A.P. Carson, A.M.  
355 Chamberlain, A.R. Chang, S. Cheng, S.R. Das, F.N. Delling, L. Djousse, M.S.V. Elkind, J.F. Ferguson,  
356 M. Fornage, L.C. Jordan, S.S. Khan, B.M. Kissela, K.L. Knutson, T.W. Kwan, D.T. Lackland, T.T.  
357 Lewis, J.H. Lichtman, C.T. Longenecker, M.S. Loop, P.L. Lutsey, S.S. Martin, K. Matsushita, A.E.  
358 Moran, M.E. Mussolino, M. O’Flaherty, A. Pandey, A.M. Perak, W.D. Rosamond, G.A. Roth, U.K.A.  
359 Sampson, G.M. Satou, E.B. Schroeder, S.H. Shah, N.L. Spartano, A. Stokes, D.L. Tirschwell, C.W.  
360 Tsao, M.P. Turakhia, L.B. VanWagner, J.T. Wilkins, S.S. Wong, S.S. Virani, Heart disease and  
361 stroke statistics-2019 Update: A report from the American Heart Association, *Circulation*. 139  
362 (10) (2019) e56-e528. <https://doi.org/10.1161/CIR.0000000000000659>.

363 [2]G. Hindricks, T. Potspara, N. Dagres, E. Arbelo, J.J. Bax, C. Blomström-Lundqvist, G. Boriani,  
364 M. Castella, G.-A. Dan, P.E. Dilaveris, L. Fauchier, G. Filippatos, J.M. Kalman, M. La Meir, D.A.  
365 Lane, J.P. Lebeau, 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation  
366 developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS),  
367 *Eur. Heart J.* 42 (2020) 373-498. <https://doi.org/10.1093/eurheartj/ehaa612>.

368 [3]H. Calkins, G. Hindricks, R. Cappato, Y.H. Kim, E.B. Saad, L. Aguinaga, J.G. Akar, V. Badhwar, J.  
369 Brugada, J. Camm, P.S. Chen, S.A. Chen, M.K. Chung, J.C. Nielsen, A.B. Curtis, D.W. Davies, J.D.  
370 Day, A. d’Avila, N.M.S. (Natasja) de Groot, L. Di Biase, M. Duytschaever, J.R. Edgerton, K.A.

371 Ellenbogen, P.T. Ellinor, S. Ernst, G. Fenelon, E.P. Gerstenfeld, D.E. Haines, M. Haissaguerre, R.H.  
372 Helm, E. Hylek, W.M. Jackman, J. Jalife, J.M. Kalman, J. Kautzner, H. Kottkamp, K.H. Kuck, K.  
373 Kumagai, R. Lee, T. Lewalter, B.D. Lindsay, L. Macle, M. Mansour, F.E. Marchlinski, G.F. Michaud,  
374 H. Nakagawa, A. Natale, S. Nattel, K. Okumura, D. Packer, E. Pokushalov, M.R. Reynolds, P.  
375 Sanders, M. Scanavacca, R. Schilling, C. Tondo, H.M. Tsao, A. Verma, D.J. Wilber, T. Yamane, 2017  
376 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation  
377 of atrial fibrillation: Executive summary, *J. Arrhythmia*. 33 (5) (2017) 369–409.  
378 <https://doi.org/10.1016/j.joa.2017.08.001>.

379 [4]T. Baykaner, A.J. Rogers, G.L. Meckler, J. Zaman, R. Navara, M. Rodrigo, M. Alhusseini, C.A.B.  
380 Kowalewski, M.N. Viswanathan, S.M. Narayan, P. Clopton, P.J. Wang, P.A. Heidenreich, *Clinical*  
381 *implications of ablation of drivers for atrial fibrillation*, *Circ. Arrhythmia Electrophysiol.* 11 (2018)  
382 e006119. <https://doi.org/10.1161/CIRCEP.117.006119>.

383 [5]M. Haissaguerre, M. Hocini, A. Denis, A.J. Shah, Y. Komatsu, S. Yamashita, M. Daly, S. Amraoui,  
384 S. Zellerhoff, M.Q. Picat, A. Quotb, L. Jesel, H. Lim, S. Ploux, P. Bordachar, G. Attuel, V. Meillet,  
385 P. Ritter, N. Derval, F. Sacher, O. Bernus, H. Cochet, P. Jais, R. Dubois, *Driver domains in*  
386 *persistent atrial fibrillation*, *Circulation*. 130 (2014) 530–538.  
387 <https://doi.org/10.1161/CIRCULATIONAHA.113.005421>.

388 [6]S.M. Narayan, D.E. Krummen, K. Shivkumar, P. Clopton, W.J. Rappel, J.M. Miller, *Treatment*  
389 *of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for*  
390 *Atrial Fibrillation with or Without Focal Impulse and Rotor Modulation) trial*, *J. Am. Coll. Cardiol.*  
391 60 (7) (2012) 628–636. <https://doi.org/10.1016/j.jacc.2012.05.022>.

392 [7]S.M. Narayan, D.E. Krummen, P. Clopton, K. Shivkumar, J.M. Miller, *Direct or coincidental*  
393 *elimination of stable rotors or focal sources may explain successful atrial fibrillation ablation:*  
394 *On-treatment analysis of the CONFIRM trial (Conventional Ablation for AF with or Without Focal*

395 Impulse and Rotor Modulation), J. Am. Coll. Cardiol. 62 (2) (2013) 138–147.  
396 <https://doi.org/10.1016/j.jacc.2013.03.021>.

397 [8]M. Rodrigo, A.M. Climent, I. Hernández-Romero, A. Liberos, T. Baykaner, A.J. Rogers, M.  
398 Alhousseini, P.J. Wang, F. Fernández-Avilés, M.S. Guillem, S.M. Narayan, F. Atienza, Noninvasive  
399 assessment of complexity of atrial fibrillation: correlation with contact mapping and impact of  
400 ablation, Circ. Arrhythmia Electrophysiol. 13 (2020) e007700.  
401 <https://doi.org/10.1161/CIRCEP.119.007700>.

402 [9]X. Gao, A.G. Lam, K.C. Bilchick, A. Darby, N. Mehta, P.K. Mason, R. Malhotra, J.M. Mangrum,  
403 The use of non-invasive mapping in persistent AF to predict acute procedural outcome, J.  
404 Electrocardiol. 57 (2019) S21–S26. <https://doi.org/10.1016/j.jelectrocard.2019.08.012>.

405 [10]F. Remondino, 3-D reconstruction of static human body shape from image sequence,  
406 Comput. Vis. Image Underst. 93 (1) (2004) 65–85. <https://doi.org/10.1016/j.cviu.2003.08.006>.

407 [11]P.A. Yushkevich, H. Zhang, J.C. Gee, Continuous medial representation for anatomical  
408 structures, IEEE Trans. Med. Imaging. 25 (12) (2006) 1547–1564.  
409 <https://doi.org/10.1109/TMI.2006.884634>.

410 [12]F. Castells, C. Mora, J.J. Rieta, D. Moratal-Pérez, J. Millet, Estimation of atrial fibrillatory wave  
411 from single-lead atrial fibrillation electrocardiograms using principal component analysis  
412 concepts, Med. Biol. Eng. Comput. 43 (2005) 557–560. <https://doi.org/10.1007/BF02351028>.

413 [13]M. Rodrigo, M.S. Guillem, A.M. Climent, A. Liberos, I. Hernández-Romero, Á. Arenal, J.  
414 Bermejo, F. Fernández-Avilés, F. Atienza, M.S. Guillem, Solving inaccuracies in anatomical  
415 models for electrocardiographic inverse problem resolution by maximizing reconstruction  
416 quality, IEEE Trans. Med. Imaging. 37 (3) (2018) 733–740.  
417 <https://doi.org/10.1109/TMI.2017.2707413>.

418 [14]M. Rodrigo, A.M. Climent, A. Liberos, F. Fernández-Avilés, O. Berenfeld, F. Atienza, M.S.  
419 Guillem, Technical considerations on phase mapping for identification of atrial reentrant activity

420 in direct- and inverse-computed electrograms, *Circ. Arrhythmia Electrophysiol.* 10 (2017)  
421 e005008. <https://doi.org/10.1161/CIRCEP.117.005008>.

422 [15]I. Jekova, V. Krasteva, R. Leber, R. Schmid, R. Twerenbold, C. Müller, T. Reichlin, R. Abächerli,  
423 Intersubject variability and intrasubject reproducibility of 12-lead ECG metrics: implications for  
424 human verification, *J. Electrocardiol.* 49 (6) (2016) 784–789.  
425 <https://doi.org/10.1016/j.jelectrocard.2016.07.021>.

426 [16]S. Choudry, M. Mansour, S. Sundaram, D.T. Nguyen, S.R. Dukkupati, W. Whang, P. Kessman,  
427 V.Y. Reddy, RADAR: A multicenter food and drug administration investigational device  
428 exemption clinical trial of persistent atrial fibrillation, *Circ. Arrhythmia Electrophysiol.* 13 (2020)  
429 7e00825. <https://doi.org/10.1161/CIRCEP.119.007825>.

430 [17] M.Rodrigo, A. M. Climent, A. Liberos, F. Fernández-Avilés, F. Atienza, M.S. Guillem, O.  
431 Berenfeld: Minimal configuration of body surface potential mapping for discrimination of left  
432 versus right dominant frequencies during atrial fibrillation, *Pacing Clin Electrophysiol.* 40 (2017)  
433 940–946. <https://doi.org/10.1111/pace.13133>

434 [18]M. S. Guillem, A. Bollmann, A. M. Climent, D. Husser, J. Millet-Roig, F. Castells, How Many  
435 Leads Are Necessary for a Reliable Reconstruction of Surface Potentials During Atrial  
436 Fibrillation?, *IEEE Trans. Inf. Technol. Biomed.* 13 (3) (2009) 330-340. doi:  
437 [10.1109/TITB.2008.2011894](https://doi.org/10.1109/TITB.2008.2011894).

438 [19]J.A.B. Zaman, T. Baykaner, P. Clopton, V. Swarup, R.C. Kowal, J.P. Daubert, J.D. Day, J.  
439 Hummel, A.A. Schricker, D.E. Krummen, M. Mansour, G.F. Tomassoni, K.R. Wheelan, M.  
440 Vishwanathan, S. Park, P.J. Wang, S.M. Narayan, J.M. Miller, Recurrent post-ablation paroxysmal  
441 atrial fibrillation shares substrates with persistent atrial fibrillation: an 11-center study, *JACC*  
442 *Clin. Electrophysiol.* 3 (4) (2017) 393–402. <https://doi.org/10.1016/j.jacep.2016.10.006>

443 [20]S. Zeemering, A. van Hunnik, F. van Rosmalen, P. Bonizzi, B. Scaf, T. Delhaas, S. Verheule, U.  
444 Schotten, A novel tool for the identification and characterization of repetitive patterns in high-

445 density contact mapping of atrial fibrillation, *Front. Physiol.* 11 (2020) 1–12.  
446 <https://doi.org/10.3389/fphys.2020.570118>.

447 [21]H.S. Lim, M. Hocini, R. Dubois, A. Denis, N. Derval, S. Zellerhoff, S. Yamashita, B. Berte, S.  
448 Mahida, Y. Komatsu, M. Daly, L. Jesel, C. Pomier, V. Meillet, S. Amraoui, A.J. Shah, H. Cochet, F.  
449 Sacher, P. Jaïs, M. Haïssaguerre, Complexity and distribution of drivers in relation to duration of  
450 persistent atrial fibrillation, *J. Am. Coll. Cardiol.*, 69 (10) (2017) 1257-1269.  
451 <https://doi.org/10.1016/j.jacc.2017.01.014>.

452 [22]P. Bonizzi, S. Zeemering, J.M.H. Karel, L.Y. Di Marco, L. Uldry, J. Van Zaen, J.M. Vesin, U.  
453 Schotten, Systematic comparison of non-invasive measures for the assessment of atrial  
454 fibrillation complexity: a step forward towards standardization of atrial fibrillation electrogram  
455 analysis, *Europace.* 17 (2) (2015) 318–325. <https://doi.org/10.1093/europace/euu202>.

456 [23]M. Meo, T. Pambrun, N. Derval, C. Dumas-Pomier, S. Puyo, J. Duchâteau, P. Jaïs, M. Hocini,  
457 M. Haïssaguerre, R. Dubois, Noninvasive assessment of atrial fibrillation complexity in relation  
458 to ablation characteristics and outcome, *Front. Physiol.* 9 (929) (2018).  
459 <https://doi.org/10.3389/fphys.2018.00929>.

460 [24]J. Seitz, C. Bars, G. Théodore, S. Beurtheret, N. Lellouche, M. Bremond, A. Ferracci, J. Faure,  
461 G. Penaranda, M. Yamazaki, U.M.R. Avula, L. Curel, S. Siame, O. Berenfeld, A. Pisapia, J. Kalifa,  
462 AF ablation guided by spatiotemporal electrogram dispersion without pulmonary vein isolation:  
463 a wholly patient-tailored approach, *J. Am. Coll. Cardiol.* 69 (3) (2017) 303–321.  
464 <https://doi.org/10.1016/j.jacc.2016.10.065>.

465 [25]T. Lankveld, C.B. De Vos, I. Limantoro, S. Zeemering, E. Dudink, H.J. Crijns, U. Schotten,  
466 Systematic analysis of ECG predictors of sinus rhythm maintenance after electrical cardioversion  
467 for persistent atrial fibrillation, *Hear. Rhythm.* 13 (5) (2016) 1020–1027.  
468 <https://doi.org/10.1016/j.hrthm.2016.01.004>.